Trials / Completed
CompletedNCT02296580
A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Nativis, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This feasibility study will assess the effects of the Nativis Voyager therapy in patients with first or second recurrence of GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab. Safety and clinical utility will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Nativis Voyager RFE Therapy | Nativis Voyager Radiofrequency Energy Therapy |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2014-11-20
- Last updated
- 2023-02-02
Locations
13 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02296580. Inclusion in this directory is not an endorsement.